Neuren Pharmaceuticals Ltd (NEU.AX) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · Australia · ISIN NZNEUE0001S8

Price
20.16 AUD
Market cap
2.64 bn AUD
P/E (2025)
86.62
P/S (2025)
40.79
Dividend yield
0.74 %
Net margin
47.09 %
Return on equity (ROE)
8.99 %
Return on assets (ROA)
8.88 %

Neuren Pharmaceuticals Ltd financials

Fiscal year20242025
Revenue213.24 m AUD64.63 m AUD
Gross profit213.22 m AUD64.61 m AUD
Operating income175.55 m AUD22.02 m AUD
EBIT175.55 m AUD22.02 m AUD
Net income142.04 m AUD30.44 m AUD
Diluted EPS – continuing operations1.09 AUD0.23 AUD

Full history since 2000, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Neuren Pharmaceuticals Ltd

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.